The first clinical results of an ongoing, prospective trial to determine the value of adjuvant Bestatin immunotherapy in the management of bladder cancer are presented. Patients with nonmetastatic transitional cell carcinoma of the bladder, scheduled for full dose local radiation therapy (64 Gy), we
Cellular fibronectin in patients with transitional cell carcinoma of the bladder
✍ Scribed by Axel Hegele; Axel Heidenreich; Zoltan Varga; Rolf von Knobloch; Peter Olbert; Jürgen Kropf; Rainer Hofmann
- Publisher
- Springer-Verlag
- Year
- 2003
- Tongue
- English
- Weight
- 180 KB
- Volume
- 30
- Category
- Article
- ISSN
- 2194-7228
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The cellular immunocompetence was examined by means of the quantitative DNCB hypersensitivity reaction in 152 patients with transitional cell carcinomas of the bladder of Broders grades 1-4. Against a control group of 367 normal controls of both sexes, 85 patients with transitional cell carcinomas o
The cytoxicity in vitro fo peripheral blood lymphocytes from patients with carcinoma of the urinary bladder (TCC-bladder) against allogeneic target cells from established cell lines was studied by the 51Cr-release assay. Lymphocytes from both untreated and treated TCC-bladder patients have a signifi
Sixty-nine patients who underwent nephroureterectomy for upper urinary tract transitional cell carcinoma were included in the study. The following data were collected for each patient: grade and stage of renalhreteral tumor, tumor location, timing of tumor appearance and recurrence in the bladder, g